Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intest (INTT) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Intest (INTT) over the last 16 years, with Q3 2025 value amounting to $16.2 million.

  • Intest's Cash & Equivalents fell 969.29% to $16.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year decrease of 969.29%. This contributed to the annual value of $19.8 million for FY2024, which is 5618.65% down from last year.
  • Latest data reveals that Intest reported Cash & Equivalents of $16.2 million as of Q3 2025, which was down 969.29% from $19.2 million recorded in Q2 2025.
  • In the past 5 years, Intest's Cash & Equivalents registered a high of $45.3 million during Q4 2023, and its lowest value of $10.0 million during Q3 2022.
  • Its 5-year average for Cash & Equivalents is $21.1 million, with a median of $18.7 million in 2021.
  • In the last 5 years, Intest's Cash & Equivalents soared by 31527.2% in 2023 and then crashed by 5688.62% in 2024.
  • Over the past 5 years, Intest's Cash & Equivalents (Quarter) stood at $21.2 million in 2021, then plummeted by 31.23% to $14.6 million in 2022, then skyrocketed by 210.51% to $45.3 million in 2023, then plummeted by 56.19% to $19.8 million in 2024, then decreased by 18.15% to $16.2 million in 2025.
  • Its Cash & Equivalents stands at $16.2 million for Q3 2025, versus $19.2 million for Q2 2025 and $22.0 million for Q1 2025.